Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Green Discloses License Negotiations with Seed Company

Premium

Rosetta Green announced this week that it is negotiating a deal under which “one of the world's largest seed companies” would license a “limited” number of microRNAs identified by Rosetta Green as potentially improving key traits within an undisclosed crop plant.

If an agreement is signed and the undisclosed seed company markets products incorporating the miRNA technology, Rosetta Green would be paid milestones and royalties.

Rosetta Green said that “if the negotiation between the parties will be successful, an agreement will be signed and executed in the near term,” but added that there is no guarantee this will occur.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.